当前位置:首页 / LISA技术联合DUOPAP治疗新生儿呼吸窘迫综合征的临床效果
论著·临床研究 | 更新时间:2024-12-30
|
LISA技术联合DUOPAP治疗新生儿呼吸窘迫综合征的临床效果
Clinical effect of LISA technique combined with DUOPAP for the treatment of neonatal respiratory distress syndrome

广西医学 页码:1670-1675

作者机构:吴战朋,硕士,住院医师,研究方向为儿童呼吸。

基金信息:连云港市妇幼健康科研项目(F202106)

DOI:10.11675/j.issn.0253⁃4304.2024.11.06

  • 中文简介
  • 英文简介
  • 参考文献

目的 观察微创肺表面活性物质给药(LISA)技术联合双水平气道正压通气(DUOPAP)在新生儿呼吸窘迫综合征(NRDS)中的应用效果。方法 选取80例NRDS患儿作为研究对象,将其随机分为LISA+DUOPAP组和气管插管⁃肺表面活性物质给药⁃拔管(INSURE)+经鼻持续气道正压通气(NCPAP)组,各40例。比较治疗前后两组患儿的血气分析指标,以及给药过程中不良反应发生情况、住院相关指标、临床疗效、并发症发生情况。结果 治疗后,两组患儿的PaO2、pH值较治疗前升高,且LISA+DUOPAP组的PaO2、pH值高于INSURE+NCPAP组;治疗后,两组患儿的PaCO2较治疗前降低,且LISA+DUOPAP组的PaCO2低于INSURE+NCPAP组(P<0.05)。给药过程中,LISA+DUOPAP组的药物返流率低于INSURE+NCPAP组(P<0.05),但两组的二氧化碳潴留、心动过缓发生率差异无统计学意义(P>0.05)。LISA+DUOPAP组的辅助通气时间、总用氧时间、住院时间、住院费用短于或低于INSURE+NCPAP组(P<0.05)。两组治疗总有效率差异无统计学意义(P>0.05)。LISA+DUOPAP组的总并发症发生率低于INSURE+NCPAP组(P<0.05),但两组的各并发症(支气管肺发育不良、早产儿脑室周围⁃脑室内出血、早产儿视网膜病变、新生儿坏死性小肠结肠炎)发生率差异无统计学意义(P>0.05)。结论 与INSURE技术联合NCPAP相比,采用LISA技术联合DUOPAP治疗NRDS,可以更好地改善患儿的血气指标和氧合情况,缩短住院时间,减少住院费用,降低总并发症发生率。

Objective To observe the application effect of less invasive surfactant administration (LISA) technique combined with duo positive airway pressure (DUOPAP) in neonatal respiratory distress syndrome (NRDS). Methods A total of 80 children with NRDS were selected as the research subjects, and they were randomly assigned to LISA+DUOPAP group or intubation⁃surfactant⁃extubation (INSURE)+nasal continuous positive airway pressure (NCPAP) group, with 40 cases in each group. The pre⁃ and post⁃treatment blood gas analysis indices, and adverse reactions, indices related to hospitalization, clinical efficacy, and occurrence states of complications during administration were compared between children of the two groups. Results After treatment, both groups exhibited elevated PaO2 and pH value as compared with before treatment, and the LISA+DUOPAP group yielded higher PaO2 and pH value as compared with the INSURE+NCPAP group; in addition, both groups presented a decreased PaCO2 as compared with before treatment, and the LISA+DUOPAP group interpreted a lower PaCO2 as compared with the INSURE+NCPAP group (P<0.05). During administration, the LISA+DUOPAP group depicted a lower drug reflux rate as compared with the INSURE+NCPAP group (P<0.05), but there was no statistically significant difference in the incidence rate of carbon dioxide retention and bradycardia between the two groups (P>0.05). The LISA+DUOPAP group indicated shorter adjuvant ventilation time, total oxygen use time, length of hospital stay, and a lower total hospitalization expense as compared with the INSURE+NCPAP group (P<0.05), but there was no statistically significant difference in the total effective rate between the two groups (P>0.05). The total incidence rate of complications in the LISA+DUOPAP group was lower than that in the INSURE+NCPAP group (P<0.05), but there was no statistically significant difference in the incidence rate of various complications (bronchopulmonary dysplasia, premature periventricular intraventricular hemorrhage, retinopathy of prematurity, neonatal necrotizing enterocolitis) between the two groups (P>0.05). Conclusion Compared with INSURE technique combined with NCPAP, LISA technique combined with DUOPAP for the treatment of NRDS can preferably ameliorate blood gas indices and oxygenation, shorten length of hospital stay, reduce hospitalization expense, and decrease the total incidence rate of complications.

98

浏览量

15

下载量

0

CSCD

工具集